Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Exploration, Development and Optimization of Eco-friendly Novel Dosage Form – Pastilles

Author(s): Hardik Rana*, Poonam Panchal, Mansi Dholakia and Vaishali Thakkar

Volume 18, Issue 2, 2023

Published on: 28 October, 2022

Page: [117 - 131] Pages: 15

DOI: 10.2174/1574885517666221006105306

Price: $65

Abstract

Background: Now-a-day, there is a need to explore the concept of green chemistry in every field. Many existing conventional and novel drug delivery systems have problems related to green chemistry. Anewer natural dosage form pastilles were explored to overcome the existing limitations of the different dosage forms.

Objective: The present study aims to optimize the Glipizide (GPZ) matrix pastilles using waxy erodible polymers, integrating the concept of quality by design (QbD) and green chemistry.

Methods: The pastilles were formulated using the fabricated lab-scale pastillator. GPZ was used as a model drug. The concern related to the drug is low aqueous solubility and short variable half-life. The solubility of the drug was improved by formulating a complex between GPZ and chemically modified ß –cyclodextrin (β-CD) - hydroxypropyl-ß-cyclodextrin (HP-ß-CD). The complex was prepared using the kneading method. The complex was formulated and incorporated in different stoichiometric ratios of GPZ: complexing agent. Sustained-release pastille was formulated using Gelucire 43/01 (GC 43/01) as a release retardant polymer. The central composite design was used to obtain an optimum batch, using the amount of GC 43/01 and temperature as independent variables, while drug release at 2h, 6h, and 10h was chosen as dependent variables. The design batches were evaluated for post-and pre formulation parameters. An optimum formulation was evaluated for the influence of hydroalcoholic media on drug release.

Results: The complex formulated using HP-ß-CD (1:1) shown better solubility (36.5 mg/ml) and dissolution. The complex was incorporated in the pastilles with erodible polymer GC 43/01. The formulation was found robust with optimum pre and post-formulation parameters. An optimized batch was chosen from the design space of central composite design. The drug release of the optimized formulation was found 29.13%, 57.29% and 85.70% at 2, 6 and 10 hrs respectively, similar to the drug release of the marketed formulation. As the amount of alcohol increased from 5 to 40 %, the drug release also increased but did not show a dose dumping effect. It was due to the altered solubility of GPZ in alcohol.

Conclusion: The new formulation, Pastilles of GPZ were developed incorporating the waxy erodible polymer. Pastilles were capable of controlling drug release for up to 12 h. The amount of GC 43/01 and temperature had a significant effect on the formulation of GPZ sustained-release pastille. The newer approach of formulating pastilles might apply to the industry as it is an eco-friendly, single-step process with fewer excipients.

Keywords: Pastilles, green, chemistry, GPZ, GC 43/01, HP- ß –CD.

Next »
Graphical Abstract

[1]
Shaikh R, O’Brien DP, Croker DM, Walker GM. The development of a pharmaceutical oral solid dosage forms. Computer-Aided Chem Eng 2018; 41: 27-65.
[http://dx.doi.org/10.1016/B978-0-444-63963-9.00002-6]
[2]
Zhang J, Xie Z, Zhang N, Zhong J. Nanosuspension drug delivery system: preparation, characterization, postproduction processing, dosage form, and application. In: Nanostructures for Drug Delivery. Elsevier Inc. 2017; pp. 413-43.
[http://dx.doi.org/10.1016/B978-0-323-46143-6.00013-0]
[3]
Sampath KP, Bhowmik D, Srivastava S. Sustained release drug delivery system potential. Pharma Innov 2012; 1(2): 48-60.
[4]
Pandit AP, Chavan TT, Khandelwal KR. Enhancement of solubility, dissolution rate and bioavailability of atorvastatin using solid lipid: In vitro and in vivo characterization. J Pharm Investig 2015; 45(6): 503-13.
[http://dx.doi.org/10.1007/s40005-015-0199-7]
[5]
Silva FC, Marto JM, Salgado A, Machado P, Silva AN, Almeida AJ. Nystatin and lidocaine pastilles for the local treatment of oral mucositis. Pharm Dev Technol 2017; 22(2): 266-74.
[http://dx.doi.org/10.1080/10837450.2016.1221424] [PMID: 27499389]
[6]
Katona G, Sipos P, Frohberg P, Ulrich J, Szabó-Révész P, Jójárt-Laczkovich O. Study of paracetamol-containing pastilles produced by melt technology. J Therm Anal Calorim 2016; 123(3): 2549-59.
[http://dx.doi.org/10.1007/s10973-015-5223-7]
[7]
Hosseinkhani H, Domb AJ. Biodegradable polymers in gene‐silencing technology. Polym Adv Technol 2019; 30(10): 2647-55.
[http://dx.doi.org/10.1002/pat.4713]
[8]
Abedini F, Ebrahimi M, Roozbehani AH, Domb AJ, Hosseinkhani H. Overview on natural hydrophilic polysaccharide polymers in drug delivery. Polym Adv Technol 2018; 29(10): 2564-73.
[http://dx.doi.org/10.1002/pat.4375]
[9]
Tiwari R, Agarwal SK, Tiwari S. Formulation and multivariate optimization of microcrystalline cellulose pellets of highly water soluble drug. Int J Drug Deliv 2013; 5: 206-13.
[10]
Silva A C, Marto J, Salgado A. Nystatin-lidocaine sugar free pastilles: a stability and characterisation study. Eur J Hosp Pharm 2016; 23(S1): A208.1.
[http://dx.doi.org/10.1136/ejhpharm-2016-000875.470]
[11]
Dash TR, Verma P. Matrix tablets: An approach towards oral extended release drug delivery. Int J Pharma Res Rev 2013; 2(2): 12-24.
[12]
Radhika P, Pal T, Sivakumar T. Formulation and evaluation of sustained release matrix tablets of glipizide. Iran J Pharm Sci 2009; 5(4): 205-14.
[13]
Farmoudeh A, Rezaeiroshan A, Abbaspour M, Nokhodchi A, Ebrahimnejad P. Solid dispersion pellets: An efficient pharmaceutical approach to enrich the solubility and dissolution rate of deferasirox. BioMed Res Int 2020; 2020: 1-12.
[http://dx.doi.org/10.1155/2020/8583540] [PMID: 32685534]
[14]
Tekade AR, Yadav JN. A review on solid dispersion and carriers used therein for solubility enhancement of poorly water soluble drugs. Adv Pharm Bull 2020; 10(3): 359-69.
[http://dx.doi.org/10.34172/apb.2020.044] [PMID: 32665894]
[15]
Mohandoss S, Atchudan R, Edison TNJI, et al. Enhancement of solubility, antibiofilm, and antioxidant activity of uridine by inclusion in β-cyclodextrin derivatives. J Mol Liq 2020; 306: 112849.
[http://dx.doi.org/10.1016/j.molliq.2020.112849]
[16]
Kim DS, Cho JH, Park JH, et al. Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate. Int J Nanomedicine 2019; 14: 4949-60.
[http://dx.doi.org/10.2147/IJN.S211014] [PMID: 31308665]
[17]
Zhang XN. Bei, Zhou, et al. Application of the central composite design to optimize the preparation of novel micelles of harmine. Int J Nanomedicine 2013; 8: 1795-808.
[http://dx.doi.org/10.2147/IJN.S43555] [PMID: 23674893]
[18]
Zhang X, Xing H, Zhao Y, Ma Z. Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs. Pharmaceutics 2018; 10(3): 74.
[http://dx.doi.org/10.3390/pharmaceutics10030074] [PMID: 29937483]
[19]
Wendt K, Petersen S, Ulrich J. Influence of seeding on concentration distribution within pastilles drop formed out of binary melts. Chem Eng Sci 2015; 133: 70-4.
[http://dx.doi.org/10.1016/j.ces.2015.01.007]
[20]
Goldhaber S, Ageno W, Casella I, et al. Efficacy and safety of dabigatran etexilate versus vitamin K antagonist for treatment of acute venous thromboembolism in routine clinical practice: Recovery Dvt/Pe prospective global cohort study. J Am Coll Cardiol 2020; 75(11): 2195.
[http://dx.doi.org/10.1016/S0735-1097(20)32822-9]
[21]
Patel H, Panchal DR, Patel U, Brahmbhatt T, Suthar M. Matrix type drug delivery system : A review. J Pharm Sci Biosci Res 2011; 1(3): 143-51.
[22]
Fukuda M, Peppas NA, McGinity JW. Floating hot-melt extruded tablets for gastroretentive controlled drug release system. J Control Release 2006; 115(2): 121-9.
[http://dx.doi.org/10.1016/j.jconrel.2006.07.018] [PMID: 16959356]
[23]
Kalam MA, Alshamsan A, Alkholief M, et al. Solubility measurement and various solubility parameters of glipizide in different neat solvents. ACS Omega 2020; 5(3): 1708-16.
[http://dx.doi.org/10.1021/acsomega.9b04004] [PMID: 32010845]
[24]
Chaudhary VB, Patel JK. Cyclodextrin inclusion complex to enhance solubility of poorly water soluble drugs: a review. Int J Pharm Sci Res 2013; 4(1): 68-76.
[25]
Gupta MM, Khoorban A, Ali A, Ramlogan O, Talukdar D. Comparative quality control study of different brands of diclofenac sodium tablet available in local and government pharmacies by in-vitro testing. Cureus 2020; 12(11): e11348.
[http://dx.doi.org/10.7759/cureus.11348] [PMID: 33304683]
[26]
van der Merwe J, Steenekamp J, Steyn D, Hamman J. The role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability. Pharmaceutics 2020; 12(5): 393-409.
[http://dx.doi.org/10.3390/pharmaceutics12050393] [PMID: 32344802]
[27]
Sbârcea L, Tănase IM, Ledeți A, et al. Encapsulation of risperidone by methylated β-cyclodextrins: physicochemical and molecular modeling studies. Molecules 2020; 25(23): 5694-708.
[http://dx.doi.org/10.3390/molecules25235694] [PMID: 33287127]
[28]
Arnaout OM, Rahme RJ, El Ahmadieh TY, Aoun SG, Batjer HH, Bendok BR. Past, present, and future perspectives on the endovascular treatment of acute ischemic stroke. Tech Vasc Interv Radiol 2012; 15(1): 87-92.
[http://dx.doi.org/10.1053/j.tvir.2011.12.001] [PMID: 22464307]
[29]
Tekade RK, Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: Taguchi orthogonal array based design. BioMed Res Int 2013; 2013: 1-18.
[http://dx.doi.org/10.1155/2013/712678] [PMID: 24106715]
[30]
Nie S, Zhang S, Pan W, Liu Y. In vitro and in vivo studies on the complexes of glipizide with water-soluble β-cyclodextrin–epichlorohydrin polymers. Drug Dev Ind Pharm 2011; 37(5): 606-12.
[http://dx.doi.org/10.3109/03639045.2010.533277] [PMID: 21469949]
[31]
Yan HX, Zhang SS, He JH, Liu JP. Application of ethyl cellulose, microcrystalline cellulose and octadecanol for wax based floating solid dispersion pellets. Carbohydr Polym 2016; 148(1): 143-52.
[http://dx.doi.org/10.1016/j.carbpol.2016.04.050] [PMID: 27185125]
[32]
Dash RN, Mohammed H, Humaira T, Ramesh D. Design, optimization and evaluation of glipizide solid self-nanoemulsifying drug delivery for enhanced solubility and dissolution. Saudi Pharm J 2015; 23(5): 528-40.
[http://dx.doi.org/10.1016/j.jsps.2015.01.024] [PMID: 26594119]
[33]
Yurtdaş KG. Host-guest inclusion complex of desloratadine with 2-(hydroxy)propyl-?-cyclodextrin (HP-?-CD): Preparation, binding behaviors and dissolution properties. J Res Pharm 2020; 24(5): 693-707.
[http://dx.doi.org/10.35333/jrp.2020.224]
[34]
Mahajan HS, Dhamne MR, Gattani SG, Rasal AD, Shaikh HT. Enhanced dissolution rate of glipizide by a liquisolid technique. Int J Pharm Sci Nanotechnol 2011; 3(4): 1205-13.
[http://dx.doi.org/10.37285/ijpsn.2010.3.4.5]
[35]
Ali MT, Fule R, Sav A, Amin P. Porous starch: a novel carrier for solubility enhancement of carbamazepine. AAPS PharmSciTech 2013; 14(3): 919-26.
[http://dx.doi.org/10.1208/s12249-013-9985-6] [PMID: 23715951]
[36]
Patel N, Thakkar V, Moradiya P, Gandhi T, Gohel M. Optimization of curcumin loaded vaginal in-situ hydrogel by box-behnken statistical design for contraception. J Drug Deliv Sci Technol 2015; 29(1): 55-69.
[http://dx.doi.org/10.1016/j.jddst.2015.06.002]
[37]
Ibrahim MA, El-Badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J 2014; 22(2): 149-56.
[http://dx.doi.org/10.1016/j.jsps.2013.01.011] [PMID: 24648827]
[38]
Behin SR, Punitha IS, Saju F. Development of matrix dispersion transdermal therapeutic system containing glipizide. Pharm Lett 2013; 5(3): 278-86.
[39]
Ratnam SV, Bhowmik D, Yadav R, Singh D. Formulation and evaluation of carvedilol fast dissolving tablets. J Chem Pharm Sci 2014; 7(2): 85-8.
[40]
Sood S, Maddiboyina B, Rawat P, et al. Enhancing the solubility of nitazoxanide with solid dispersions technique: formulation, evaluation, and cytotoxicity study. J Biomater Sci Polym Ed 2020; 0(0): 1-11.
[http://dx.doi.org/10.1080/09205063.2020.1844506] [PMID: 33226893]
[41]
Saviano AM, Lourenço FR. Design of Experiments (DoE) applied to pharmaceutical and analytical Quality by Design (QbD). Braz J Pharm Sci 2018; 54: 1-16.
[42]
Dave VS, Fahmy RM, Bensley D, Hoag SW. Eudragit® RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets. Drug Dev Ind Pharm 2012; 38(10): 1240-53.
[http://dx.doi.org/10.3109/03639045.2011.645831] [PMID: 22257339]
[43]
Dave VS, Fahmy RM, Hoag SW. Investigation of the physical–mechanical properties of Eudragit® RS PO/RL PO and their mixtures with common pharmaceutical excipients. Drug Dev Ind Pharm 2013; 39(7): 1113-25.
[http://dx.doi.org/10.3109/03639045.2012.714786] [PMID: 22994144]
[44]
Mansuri N, Patel K, Mehta M, et al. Quality by Design (QbD) approach to match tablet glossiness. Pharm Dev Technol 2020; 25(8): 1010-7.
[http://dx.doi.org/10.1080/10837450.2020.1772291] [PMID: 32432492]
[45]
Zhang C, Yang L, Wan F, et al. Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery. Int J Pharm 2020; 585: 119441.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119441] [PMID: 32442645]
[46]
Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J 2014; 16(4): 771-83.
[http://dx.doi.org/10.1208/s12248-014-9598-3] [PMID: 24854893]
[47]
Kotlowska H, Krotka J, Szymanska M, Kubiak B, Sznitowska M, Nalluri BN. The use of novel tools for the assessment of powders and granules flow properties and for the analysis of minitablets compression process. Drug Dev Ind Pharm 2020; 46(4): 547-56.
[http://dx.doi.org/10.1080/03639045.2020.1734020] [PMID: 32129090]
[48]
Ali J, Pramod K, Tahir MA, Charoo NA, Ansari SH. Pharmaceutical product development: A quality by design approach. Int J Pharm Investig 2016; 6(3): 129-38.
[http://dx.doi.org/10.4103/2230-973X.187350] [PMID: 27606256]
[49]
Stamatis DH. Failure Mode And Effect Analysis FMEA from theory to execution. (2nd ed.), Milwaukee: ASQ Quality Press 2003.
[50]
Mahdizadeh M, Zamanzade E. A new reliability measure in ranked set sampling. Stat Pap 2018; 59(3): 861-91.
[http://dx.doi.org/10.1007/s00362-016-0794-3]
[51]
Zamanzade E, Mahdizadeh M. Using ranked set sampling with extreme ranks in estimating the population proportion. Stat Methods Med Res 2020; 29(1): 165-77.
[http://dx.doi.org/10.1177/0962280218823793] [PMID: 30706764]
[52]
Zhang D, Rumondor ACF, Zhu W, et al. The development of minitablets for a pediatric dosage form for a combination therapy. J Pharm Sci 2020; 109(12): 3590-7.
[http://dx.doi.org/10.1016/j.xphs.2020.08.021] [PMID: 32882230]
[53]
Liu P, Zhou J, Chang J, et al. Soluplus-mediated diosgenin amorphous solid dispersion with high solubility and high stability: development, characterization and oral bioavailability. Drug Des Devel Ther 2020; 14: 2959-75.
[http://dx.doi.org/10.2147/DDDT.S253405] [PMID: 32801637]
[54]
Thakur K, Mahajan A, Sharma G, et al. Implementation of Quality by Design (QbD) approach in development of silver sulphadiazine loaded egg oil organogel: An improved dermatokinetic profile and therapeutic efficacy in burn wounds. Int J Pharm 2020; 576: 118977.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118977] [PMID: 31870953]
[55]
Sangshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by design approach: Regulatory need. Arab J Chem 2017; 10: S3412-25.
[http://dx.doi.org/10.1016/j.arabjc.2014.01.025]
[56]
Panda M, Rao MEB, Patra CN. Formulation and development of floating multiple-unit minitablets of nimodipine without using a gas-generating agent : In vitro and in vivo characterization. Futur J Pharm Sci 2020; 6(4): 1-9.
[http://dx.doi.org/10.1186/s43094-020-0021-x]
[57]
Wang J, Kan S, Chen T, Liu J. Application of quality by design (QbD) to formulation and processing of naproxen pellets by extrusion–spheronization. Pharm Dev Technol 2015; 20(2): 246-56.
[http://dx.doi.org/10.3109/10837450.2014.908300] [PMID: 25069591]
[58]
Middle J. A Review of: “Introduction to Quality Control.” By Kaoru Ishikawa. Translated by J. H. Loftus (Chapman and Hall, London, 1991). Int J Prod Res 1992; 30(12): 2952.
[http://dx.doi.org/10.1080/00207549208948202]
[59]
Olawoye B. A comprehensive handout on central composite design (CCD). NIST/SEMATECH e-Handbook of Statistical Methods 2016.
[60]
Central composite design - an overview from artificial intelligence and data science in environmental sensing, 2022 2021. Available from: Central Composite Design - an overview | ScienceDirect Topics
[61]
Ahmad A, Amir M, Alshadidi AA, Hussain MD, Haq A, Kazi M. Central composite design expert-supported development and validation of HPTLC method: Relevance in quantitative evaluation of protopine in Fumaria indica. Saudi Pharm J 2020; 28(4): 487-94.
[http://dx.doi.org/10.1016/j.jsps.2020.02.011] [PMID: 32273809]
[62]
Bayuo J, Abukari MA, Pelig-Ba KB, Pelig B. Optimization using Central Composite Design (CCD) of Response Surface Methodology (RSM) for biosorption of hexavalent chromium from aqueous media. Appl Water Sci 2020; 10(6): 135-46.
[http://dx.doi.org/10.1007/s13201-020-01213-3]
[63]
Gurram RK, Gandra S, Shastri NR. Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools. Eur J Pharm Sci 2016; 84(1): 146-56.
[http://dx.doi.org/10.1016/j.ejps.2016.01.021] [PMID: 26812204]
[64]
Mahdizadeh M, Zamanzade E. New goodness of fit tests for the Cauchy distribution. J Appl Stat 2017; 44(6): 1106-21.
[http://dx.doi.org/10.1080/02664763.2016.1193726]
[65]
Liu H, Hu L, Singh RP, Dave B, Chen J, Yu J. Fabrication of a novel drug-resin combination device for controlled release of dextromethorphan hydrobromide. Colloids Surf B Biointerfaces 2020; 189: 110833.
[http://dx.doi.org/10.1016/j.colsurfb.2020.110833] [PMID: 32058254]
[66]
Singh S, Baghel R S, Yadav L. A review on solid dispersion. Int J Pharm life Sci 2011; 2(9): 1078-95.
[67]
Kassem MA, Shaboury KME, Mohamed AI. Application of central composite design for the development and evaluation of chitosan-based colon targeted microspheres and in vitro characterization. Indian J Pharm Sci 2019; 81(2): 354-64.
[http://dx.doi.org/10.36468/pharmaceutical-sciences.517]
[68]
Sarrai A, Hanini S, Merzouk N, et al. Using central composite experimental design to optimize the degradation of tylosin from aqueous solution by photo-fenton reaction. Materials 2016; 9(6): 428-39.
[http://dx.doi.org/10.3390/ma9060428] [PMID: 28773551]
[69]
Charoo NA, Shamsher AAA, Zidan AS, Rahman Z. Quality by design approach for formulation development: A case study of dispersible tablets. Int J Pharm 2012; 423(2): 167-78.
[http://dx.doi.org/10.1016/j.ijpharm.2011.12.024] [PMID: 22209997]
[70]
Khanam N, Alam MI, Md Yusuf Ali QMAI, Siddiqui A. A review on optimization of drug delivery system with experimental designs. Int J Appl Pharm 2018; 10(2): 7-12.
[http://dx.doi.org/10.22159/ijap.2018v10i2.24482]
[71]
Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Technol 1980; 12(4): 214-9.
[http://dx.doi.org/10.1080/00224065.1980.11980968]
[72]
Kumar N. Shishu. D-optimal experimental approach for designing topical microemulsion of itraconazole: Characterization and evaluation of antifungal efficacy against a standardized Tinea pedis infection model in Wistar rats. Eur J Pharm Sci 2015; 67: 97-112.
[http://dx.doi.org/10.1016/j.ejps.2014.10.014] [PMID: 25445834]
[73]
Alshweiat A, Csóka II, Tömösi F, et al. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. Int J Pharm 2020; 579(1): 119166.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119166] [PMID: 32084574]
[74]
Zainol MK, Che-Esa NS. S A-H, Zamri AI, Mohd Zin Z, Abdul Majid HA. The ramification of Arabic gum and gelatine incorporation on the physicochemical properties of Belimbing Buluh (Averhoa belimbi) fruits pastilles. Food Res 2019; 4(2): 532-8.
[http://dx.doi.org/10.26656/fr.2017.4(2).319]
[75]
Chikukwa MTR, Walker RB, Khamanga SMM. Formulation and characterisation of a combination captopril and hydrochlorothiazide microparticulate dosage form. Pharmaceutics 2020; 12(8): 712-30.
[http://dx.doi.org/10.3390/pharmaceutics12080712] [PMID: 32751409]
[76]
Murugesan S, Gowramma B, Lakshmanan K, Reddy Karri VVS, Radhakrishnan A. Oral modified drug release solid dosage form with special reference to design; an overview. Curr Drug Res Rev 2020; 12(1): 16-25.
[http://dx.doi.org/10.2174/2589977511666191121094520] [PMID: 31755398]
[77]
Tamanna S, Nandi T, Shahriar R. In-vitro comparative dissolution study of different brands of levocetirizine dihydrochloride available in Bangladesh. Int J Innov Appl Stud 2019; 26(2): 556-61.
[78]
Belayneh A, Molla F, Kahsay G. Formulation and optimization of monolithic fixed-dose combination of metformin HCl and glibenclamide orodispersible tablets. Adv Pharmacol Pharm Sci 2020; 2020: 1-14.
[http://dx.doi.org/10.1155/2020/3546597] [PMID: 32259103]
[79]
Schiano S, Wu CY, Mirtic A, Reynolds G. A novel use of friability testing for characterising ribbon milling behaviour. Eur J Pharm Biopharm 2016; 104: 82-8.
[http://dx.doi.org/10.1016/j.ejpb.2016.03.034] [PMID: 27045469]
[80]
Khaled SA, Alexander MR, Irvine DJ, et al. Extrusion 3d printing of paracetamol tablets from a single formulation with tunable release profiles through control of tablet geometry. AAPS PharmSciTech 2018; 19(8): 3403-13.
[http://dx.doi.org/10.1208/s12249-018-1107-z] [PMID: 30097806]
[81]
Pandit AP, Divase G, Chavan T, Khandelwal K. Oral lipid based multiparticulate pastilles: design and effect of pore former. J Pharm Investig 2015; 45(1): 23-33.
[http://dx.doi.org/10.1007/s40005-014-0141-4]
[82]
Ghosh A, Bhaumik UK, Bose A, et al. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation. Biol Pharm Bull 2008; 31(10): 1946-51.
[http://dx.doi.org/10.1248/bpb.31.1946] [PMID: 18827360]
[83]
Omprakash B, Ajay S, Santosh G. Formulation development of venlafaxine hydrochloride extended release tablet and in vitro characterizations. Int J Pharm Tech Res 2012; 4(4): 1777-84.
[84]
Mawla N, Hanley S, Walton K, et al. Imaging of the effect of alcohol-containing media on the performance of hypromellose hydrophilic matrix tablets: comparison of direct compression and regular grades of polymer. Pharmaceutics 2020; 12(9): 889.
[http://dx.doi.org/10.3390/pharmaceutics12090889] [PMID: 32961942]
[85]
Rana HB, Gohel MC, Dholakia MS, Gandhi TR, Omri A, Thakkar VT. Vulnerability of hydro-alcoholic media on in vitro drug release from galantamine HBr pellets comprising of compritol 888 ATO and ethocel. Res J Pharm Technol 2019; 12(2): 791-8.
[http://dx.doi.org/10.5958/0974-360X.2019.00138.0]
[86]
Panigrahi KC, Patra CN, Jena GK, et al. Gelucire: A versatile polymer for modified release drug delivery system. Fut J Pharm Sci 2018; 4(1): 102-8.
[http://dx.doi.org/10.1016/j.fjps.2017.11.001]
[87]
Quadir MA, Rahman MS, Karim MZ, Akter S, Awkat MT, Reza MS. Evaluation of hydrophobic materials as matrices for controlled-release drug delivery. Pak J Pharm Sci 2003; 16(2): 17-28.
[PMID: 16414573]
[88]
Vaingankar PN, Amin PD. Development and validation of stability-indicating RP-HPLC method for simultaneous determination of metformin HCI and glimepiride in fixed-dose combination. Anal Chem Insights 2016; 11: ACI.S38137.
[http://dx.doi.org/10.4137/ACI.S38137] [PMID: 26997866]
[89]
Scioli MS, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci 2020; 7(10): 587997.
[http://dx.doi.org/10.3389/fmolb.2020.587997] [PMID: 33195435]

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy